Management of scleroderma in a New Zealand tertiary rheumatology centre: Emphasis on pulmonary complications

New Zealand Medical Journal

Volumn 120, Issue 1254, 2007, Pages

  Ng, Kristine P ^a   Gow, Peter J ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CENTROMERE ANTIBODY; METHOTREXATE; PENICILLAMINE; SCL 70 ANTIBODY; ANTIRHEUMATIC AGENT; AUTOANTIBODY;

ADULT; ARTICLE; BRONCHIECTASIS; DIFFUSE SCLERODERMA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ESOPHAGUS METASTASIS; ETHNIC DIFFERENCE; FEMALE; GASTROINTESTINAL DISEASE; HEART FAILURE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LIMITED SCLERODERMA; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NEW ZEALAND; PERITONITIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; TERTIARY HEALTH CARE; THORAX RADIOGRAPHY; URINALYSIS; CLINICAL PRACTICE; HEART DISEASE; KIDNEY DISEASE; MEDICAL AUDIT; METABOLISM; RHEUMATOLOGY; STATISTICS;

ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; FEMALE; HEART DISEASES; HUMANS; KIDNEY DISEASES; LUNG DISEASES; MALE; MEDICAL AUDIT; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; RHEUMATOLOGY; SCLERODERMA, SYSTEMIC;

EID: 34249803822     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005;118:2-10.
2. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81:139-53.
3. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437-44.
4. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest. 1996;110:1515-9.
5. Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am. 2003;29:335-49,vii.
6. Trad S, Amoura Z, Beigelman C. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum. 2006;54:184-91.
7. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis. Indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum. 1997;40:1229.
8. Harrison NK, Glanville AR, Strickland B, et al. Pulmonary involvement in systemic sclerosis: The detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTcDTPA clearance. Respir Med. 1989;83:403.
9. Silver RM, Miller KS, Kinsella MB, et al. Evaluation and management of scleroderma lung disease. Am J Med. 1990;89:470.
10. Highland KB, Silver RM. New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol. 2005;17:737-45.
11. Steen VD. Systemic sclerosis. In: The Lung in rheumatic diseases, Caynon G, Zimmerman G (eds). New York: Marcel Dekker; 1990, p279.
12. Steen VD. Advances in diagnosis of pulmonary arterial hypertension in scleroderma. Arthritis Rheum. 2005;52:3698-700
13. British Cardiac Society Guidelines and Medical Practice Committee recommendations on the management of pulmonary hypertension in clinical practice. Heart. 2001;86(Suppl 1):11-13. http://heart.bmj.com/cgi/ content/full/86/suppl_1/i1
14. Eason RJ, Tan PL, Gow PJ. Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features. Aust N Z J Med. 1981;11:657-62.
15. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-66.
16. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792-800.
17. Paramothayan NS, Lasserson TJ, Wells AU, Walters EH. Prostacyclin for pulmonary hypertension in adults. Cochrane Database Syst Rev. 2005;(2):CD002994.
18. Liu C, Chen J. Endothelin receptor antagonists for pulmonary hypertension. Cochrane Database of Systemic Reviews. 2006;3:CD004434.
19. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest. 2006;36(Suppl 3):10-15.
20. Denton CP, Gabrielli A, Peter H, et al. Long term effects of bosentan in pulmonary arterial hypertension related to connective tissue disease: the TRUST Study results. Abstract 1862. ACR. 2006.
21. Ghofrani H, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet. 2002;360:895.
22. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57.
23. Whyte K. PHARMAC not funding some treatments for rare, life threatening diseases: bosentan as an example. N Z Med J. 2005;118(1226). http://www.nzma.org.nz/journal/118-1226/1759
24. Janosik DL, Osborn TG, Moore TL, et al. Heart disease in systemic sclerosis. Semin Arthritis Rheum. 1989;19:191-200.
25. Bredemeier M, Xavier RM, Capobianco KG. Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J Rheumatol. 2004;31:286-94.
26. Jimenez SA, Sigal SH. A 15 year prospective study of treatment of rapidly progressive systemic sclerosis with D- penicillamine. J Rheumatol. 1991;18:1496-503.
27. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two year double blind randomized controlled clinical trial. Arthritis Rheum. 1999;42:1194-203.
28. Hart HH, Grigor RR, Caughey DE. Edmic differences in the prevalence of systemic lupus erythematosus. Ann Rheum Dis. 1983;42:529-32.